Learning objectives for Pharmacists:

1. List 3 logistical issues that pharmacy students struggle with while on clinical rotations.
2. Recite 3 free technologies available for preceptors to place useful information for students to access.  
3. Reflect upon the utility of using games or polling systems to improve information retention.
4. Summarize the 2018 AHA/ACC guideline recommendations on the management of cholesterol.
5. Review supported literature and discuss the role of PCSK9 inhibitors for secondary clinical ASCVD prevention. 
6. Review background information about imipenem, cilastatin, and relebactam including mechanism of action, indications, and adverse effects
7. Discuss and analyze the current available literature to determine the appropriate use of imipenem, cilastatin, and relebactam
8. Describe the proposed mechanism of action of pitolisant
9. Recognize the common dosing, dosing adjustments for special populations, drug interactions, and adverse effects of pitolisant
10. Outline the major change in the 2019 Global Initiative for Asthma (GINA) guidelines
11. Discuss budesonide-formoterol’s place in therapy for mild asthma based on recent literature
12. Review sacubitril/valsartan and supporting literature leading to FDA approval
13. Discuss new literature detailing the potential new indications/patient populations for the use of sacubitril/valsartan
14. Describe the incidence of penicillin allergies
15. Illustrate the role of the pharmacist in appropriate interventions in patients with penicillin allergies
16. Distinguish when it is appropriate to treat for a urinary tract infection (UTI) in hospitalized patients
17. Identify the outcomes associated with antibiotic treatment of hospitalized patients with asymptomatic bacteriuria
18. Evaluate evidence to support the use of rivaroxaban in chronic coronary artery disease and peripheral arterial disease
19. Discuss implications of findings of the COMPASS study for treatment of patients with chronic coronary artery disease and peripheral arterial disease
20. Explain upadacitinib's place in the treatment of rheumatoid arthritis
21. Identify appropriate dosing and monitoring for patients taking upadacitinib